Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

DNX-2401 regulatory update

August 8, 2016 7:00 AM UTC

EMA granted PRIority MEdicines (PRIME) designation to DNX-2401 from DNAtrix to treat recurrent glioblastoma. The company said in “the coming weeks” it will begin a Phase II trial evaluating DNX-2401 i...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article